Linking the beneficial effects of current therapeutic approaches in diabetes to the vascular endothelin system

Life Sciences

Volumn 118, Issue 2, 2014, Pages 129-135

  Matsumoto, Takayuki ^a   Lopes, Rheure A M ^b   Taguchi, Kumiko ^a   Kobayashi, Tsuneo ^a   Tostes, Rita C ^b  

^a HOSHI UNIVERSITY   (Japan)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Diabetes; Endothelial dysfunction; ET 1 Type 2 diabetes; Vascular smooth muscle

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ALDOSTERONE; AMINOGUANIDINE; ANGIOTENSIN; ANTIDIABETIC AGENT; ATORVASTATIN; BARDOXOLONE; CERIVASTATIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOBESILATE CALCIUM; ENDOTHELIN; ENDOTHELIN 1; ENDOTHELIN A RECEPTOR ANTAGONIST; GLITAZONE DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOSARTAN; MACITENTAN; METFORMIN; MINERALOCORTICOID ANTAGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PIOGLITAZONE; POLYPHENOL DERIVATIVE; PRAVASTATIN; RENIN; RESVERATROL; ROSIGLITAZONE; SPIRONOLACTONE; STREPTOZOCIN; UNINDEXED DRUG; [4 [2 (3 FLUORO 4 TRIFLUOROMETHYLPHENYL) 4 METHYL 5 THIAZOLYLMETHYLTHIO] 2 METHYLPHENOXY]ACETIC ACID; ENDOTHELIN RECEPTOR;

ANGIOGENESIS; ANTIDIABETIC ACTIVITY; CARDIOVASCULAR SYSTEM; DIABETES MELLITUS; DIABETIC ANGIOPATHY; DIABETIC NEPHROPATHY; DIABETIC PATIENT; DIABETIC RETINOPATHY; DRUG EFFICACY; DRUG SAFETY; GLYCEMIC CONTROL; HUMAN; INSULIN RESISTANCE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; OXIDATIVE STRESS; PATHOGENESIS; PROTEIN FUNCTION; RECEPTOR BLOCKING; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; STREPTOZOTOCIN-INDUCED DIABETES MELLITUS; VASODILATATION; ANIMAL; DIABETIC ANGIOPATHIES; METABOLISM; PATHOLOGY; VASCULAR ENDOTHELIUM;

ANIMALIA;

ANIMALS; DIABETES MELLITUS; DIABETIC ANGIOPATHIES; ENDOTHELINS; ENDOTHELIUM, VASCULAR; HUMANS; RECEPTORS, ENDOTHELIN;

EID: 84920886180     PISSN: 00243205     EISSN: 18790631     Source Type: Journal    
DOI: 10.1016/j.lfs.2013.12.216     Document Type: Review

References (134)

1. M.N. Abdul Rahman, and I.C. Chetter Statins and ischaemia reperfusion injury: a molecular biological review Curr Vasc Pharmacol 8 2010 831 835
2. M. Abuannadi, and J.H. O'Keefe Review article: eplerenone: an underused medication? J Cardiovasc Pharmacol Ther 15 2010 318 325
3. G. Ahlborg, A. Shemyakin, F. Bohm, A. Gonon, and J. Pernow Dual endothelin receptor blockade acutely improves insulin sensitivity in obese patients with insulin resistance and coronary artery disease Diabetes Care 30 2007 591 596
4. M. Ahmadian, J.M. Suh, N. Hah, C. Liddle, A.R. Atkins, and M. Downes PPARγ signaling and metabolism: the good, the bad and the future Nat Med 19 2013 557 566
5. H. Allain, A.A. Ramelet, E. Polard, and D. Bentue-Ferrer Safety of calcium dobesilate in chronic venous disease, diabetic retinopathy and haemorrhoids Drug Saf 27 2004 649 660
6. S.J. An, R. Boyd, M. Zhu, A. Chapman, D.R. Pimentel, and H.D. Wang NADPH oxidase mediates angiotensin II-induced endothelin-1 expression in vascular adventitial fibroblasts Cardiovasc Res 75 2007 702 709
7. P.V. Babu, and D. Liu Green tea catechins and cardiovascular health: an update Curr Med Chem 15 2008 1840 1850
8. A.K. Banes-Berceli, S. Ogobi, A. Tawfik, B. Patel, A. Shirley, and D.M. Pollock Endothelin-1 activation of JAK2 in vascular smooth muscle cells involves NAD(P)H oxidase-derived reactive oxygen species Vascul Pharmacol 43 2005 310 319
9. S.B. Bender, A.P. McGraw, I.Z. Jaffe, and J.R. Sowers Mineralocorticoid receptor-mediated vascular insulin resistance: an early contributor to diabetes-related vascular disease? Diabetes 62 2013 313 319
10. K. Benz, and K. Amann Endothelin in diabetic renal disease Contrib Nephrol 172 2011 139 148
11. P. Berthet, J.C. Farine, and J.P. Barras Calcium dobesilate: pharmacological profile related to its use in diabetic retinopathy Int J Clin Pract 53 1999 631 636
12. M. Briet, and E.L. Schiffrin Vascular actions of aldosterone J Vasc Res 50 2013 89 99
13. M. Brownlee, H. Vlassara, A. Kooney, P. Ulrich, and A. Cerami Aminoguanidine prevents diabetes-induced arterial wall protein cross-linking Science 232 1986 1629 1632
14. G.E. Callera, R.C. Tostes, A. Yogi, A.C. Montezano, and R.M. Touyz Endothelin-1-induced oxidative stress in DOCA-salt hypertension involves NADPH-oxidase-independent mechanisms Clin Sci 110 2006 243 253
15. C. Cardillo, U. Campia, M.B. Bryant, and J.A. Panza Increased activity of endogenous endothelin in patients with type II diabetes mellitus Circulation 106 2002 1783 1787
16. W.S. Cheang, X. Fang, and X.Y. Tian Pleiotropic effects of peroxisome proliferator-activated receptor γ and δ in vascular diseases Circ J 77 2013 2664 2671
17. Y.X. Chen, X.Q. Wang, Y. Fu, Y.J. Yao, M.Y. Kong, and R.Q. Nie Pivotal role of inflammation in vascular endothelial dysfunction of hyperlipidemic rabbit and effects by atorvastatin Int J Cardiol 146 2011 140 144
18. C. Christakou, F. Economou, S. Livadas, C. Piperi, C. Adamopoulos, and E. Marinakis Strong and positive association of endothelin-1 with AGEs in PCOS: a causal relationship or a bystander? Hormones (Athens) 10 2011 292 297
19. Y. Dai, J.L. Mehta, and M. Chen Glucagon-like peptide-1 receptor agonist liraglutide inhibits endothelin-1 in endothelial cell by repressing nuclear factor-kappa B activation Cardiovasc Drugs Ther 27 2013 371 380
20. L.V. D'Uscio, S. Shaw, M. Barton, and F. Luscher Losartan but not verapamil inhibits angiotensin II-induced tissue endothelin-1 increase: role of blood pressure and endothelial function Hypertension 31 1998 1305 1310
21. E. Diamanti-Kandarakis, and A. Dunaif Insulin resistance and the polycystic ovary syndrome revisited: an update on mechanisms and implications Endocr Rev 33 2012 981 1030
22. E. Diamanti-Kandarakis, G. Spina, C. Kouli, and I. Migdalis Increased endothelin-1 levels in women with polycystic ovary syndrome and the beneficial effect of metformin therapy J Clin Endocrinol Metab 86 2001 4666 4673
23. F. Dong, X. Zhang, L.E. Wold, Q. Ren, Z. Zhang, and J. Ren Endothelin-1 enhances oxidative stress, cell proliferation and reduces apoptosis in human umbilical vein endothelial cells: role of ETB receptor, NAD(P)H oxidase and caveolin-1 Br J Pharmacol 145 2005 323 333
24. A.M. El-Mowafy, M. Alkhalaf, and N.N. Nassar Resveratrol reverses ET-1-evoked mitogenic effects in human coronary arterial cells by activating the kinase-G to inhibit ERK-enzymes Int J Cardiol 136 2009 263 269
25. T. Emori, Y. Hirata, K. Ohta, K. Kanno, S. Eguchi, and T. Imai Cellular mechanism of endothelin-1 release by angiotensin and vasopressin Hypertension 18 1991 165 170
26. A. Ergul Endothelin-1 and diabetic complications: focus on the vasculature Pharmacol Res 63 2011 477 482
27. D.G. Farmer, and S. Kennedy RAGE, vascular tone and vascular disease Pharmacol Ther 124 2009 185 194
28. P. Ferroni, D. Della-Morte, A. Pileggi, S. Riondino, T. Rundek, and C. Ricordi Pleiotropic effects of PPARγ agonist on hemostatic activation in type 2 diabetes mellitus Curr Vasc Pharmacol 11 2013 338 351
29. J.M. Forbes, and M.E. Cooper Mechanisms of diabetic complications Physiol Rev 93 2013 137 188
30. S. Fredersdorf, D.H. Endemann, A. Luchner, D. Heitzmann, C. Ulucon, and C. Birner Increased aldosterone levels in a model of type 2 diabetes mellitus Exp Clin Endocrinol Diabetes 117 2009 15 20
31. G. Fujisawa, K. Okada, S. Muto, N. Fujita, N. Itabashi, and E. Kusano Spironolactone prevents early renal injury in streptozotocin-induced diabetic rats Kidney Int 66 2004 1493 1502
32. J.W. Funder Mineralocorticoid receptor antagonists: emerging roles in cardiovascular medicine Integr Blood Press Control 6 2013 129 138
33. E. Gagliardini, D. Corna, C. Zoja, F. Sangalli, F. Carrara, and M. Rossi Unlike each drug alone, lisinopril if combined with avosentan promotes regression of renal lesions in experimental diabetes Am J Physiol Renal Physiol 297 2009 F1448 F1456
34. X. Gao, H. Zhang, A.M. Schmidt, and C. Zhang AGE/RAGE produces endothelial dysfunction in coronary arterioles in type 2 diabetic mice Am J Physiol Heart Circ Physiol 295 2008 H491 H498
35. C. Glineur, B. Gross, B. Neve, C. Rommens, G.T. Chew, and F. Martin-Nizard Fenofibrate inhibits endothelin-1 expression by peroxisome proliferator-activated receptor α-dependent and independent mechanisms in human endothelial cells Arterioscler Thromb Vasc Biol 33 2013 621 628
36. J. Goddard, C. Eckhart, N.R. Johnston, A.D. Cumming, A.J. Rankin, and D.J. Webb Endothelin A receptor antagonism and angiotensin-converting enzyme inhibition are synergistic via an endothelin B receptor-mediated and nitric oxide-dependent mechanism J Am Soc Nephrol 15 2004 2601 2610
37. H.J. Heerspink, and D. de Zeeuw The kidney in type 2 diabetes therapy Rev Diabet Stud 8 2011 392 402
38. O. Hernandez-Perera, D. Perez-Sala, J. Navarro-Antolin, R. Sanchez-Pascuala, G. Hernandez, and C. Diaz Effects of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors, atorvastatin and simvastatin, on the expression of endothelin-1 and endothelial nitric oxide synthase in vascular endothelial cells J Clin Invest 101 1998 2711 2719
39. O. Hernandez-Perera, D. Perez-Sala, E. Soria, and S. Lamas Involvement of Rho GTPases in the transcriptional inhibition of preproendothelin-1 gene expression by simvastatin in vascular endothelial cells Circ Res 87 2000 616 622
40. U. Hink, H. Li, H. Mollnau, M. Oelze, E. Matheis, and M. Hartmann Mechanisms underlying endothelial dysfunction in diabetes mellitus Circ Res 88 2001 E14 E22
41. B. Hocher, A. Schwarz, D. Reinbacher, J. Jacobi, A. Lun, and F. Priem Effects of endothelin receptor antagonists on the progression of diabetic nephropathy Nephron 87 2001 161 169
42. N.K. Hollenberg, R. Stevanovic, A. Agarwal, M.C. Lansang, D.A. Price, and L.M. Laffel Plasma aldosterone concentration in the patient with diabetes mellitus Kidney Int 65 2004 1435 1439
43. H.J. Hong, P. Chan, J.C. Liu, S.H. Juan, M.T. Huang, and J.G. Lin Angiotensin II induces endothelin-1 gene expression via extracellular signal-regulated kinase pathway in rat aortic smooth muscle cells Cardiovasc Res 61 2004 159 168
44. M. Iglarz, R.M. Touyz, F. Amiri, M.F. Lavoie, Q.N. Diep, and E.L. Schiffrin Effect of peroxisome proliferator-activated receptor-alpha and -gamma activators on vascular remodeling in endothelin-dependent hypertension Arterioscler Thromb Vasc Biol 23 2003 45 51
45. T. Imbar, E. Klipper, C. Greenfield, A. Hurwitz, R. Haimov-Kochman, and R. Meidan Altered endothelin expression in granulosa-lutein cells of women with polycystic ovary syndrome Life Sci 91 2012 703 709
46. Y. Irukayama-Tomobe, T. Miyauchi, Y. Kasuya, S. Sakai, K. Goto, and I. Yamaguchi Activation of peroxisome proliferator-activated receptor-alpha decreases endothelin-1-induced p38 mitogen-activated protein kinase activation in cardiomyocytes J Cardiovasc Pharmacol 44 2004 S358 S361
47. Y. Irukayama-Tomobe, T. Miyauchi, S. Sakai, Y. Kasuya, T. Ogata, and M. Takanashi Endothelin-1-induced cardiac hypertrophy is inhibited by activation of peroxisome proliferator-activated receptor-alpha partly via blockade of c-Jun NH2-terminal kinase pathway Circulation 109 2004 904 910
48. M. Iwase, Y. Doi, D. Gogo, K. Ichikawa, K. Iino, and M. Yoshinari Effect of nicardipine versus enalapril on plasma endothelin-1 in hypertensive patients with type 2 diabetes mellitus Clin Exp Hypertens 22 2000 695 703
49. A. Javadzadeh, A. Ghorbanihaghjo, F.H. Adl, D. Andalib, H. Khojasteh-Jafari, and K. Ghabili Calcium dobesilate reduces endothelin-1 and high-sensitivity C-reactive protein serum levels in patients with diabetic retinopathy Mol Vis 19 2013 62 68
50. S. Jesmin, Y. Hattori, S. Maeda, S. Zaedi, I. Sakuma, and T. Miyauchi Subdepressor dose of benidipine ameliorates diabetic cardiac remodeling accompanied by normalization of upregulated endothelin system in rats Am J Physiol Heart Circ Physiol 290 2006 H2146 H2154
51. Y. Jimenez-Gomez, J.A. Mattison, K.J. Pearson, A. Martin-Montalvo, H.H. Palacious, and A.M. Sossong Resveratrol improves adipose insulin signaling and reduces the inflammatory response in adipose tissue of rhesus monkeys on high-fat, high-sugar diet Cell Metab 18 2013 533 545
52. J. Kahler, S. Mendel, J. Weckmuller, H.D. Orzechowski, C. Mittmann, and R. Koster Oxidative stress increases synthesis of big endothelin-1 by activation of the endothelin-1 promoter J Mol Cell Cardiol 32 2000 1429 1437
53. M. Kalani The importance of endothelin-1 for microvascular dysfunction in diabetes Vasc Health Risk Manag 4 2008 1061 1068
54. N. Kanie, and K. Kamata Effects of chronic administration of the novel endothelin antagonist J-104132 on endothelial dysfunction in streptozotocin-induced diabetic rat Br J Pharmacol 135 2002 1935 1942
55. N. Kanie, T. Matsumoto, T. Kobayashi, and K. Kamata Relationship between peroxisome proliferator-activated receptors (PPAR alpha and PPAR gamma) and endothelium-dependent relaxation in streptozotocin-induced diabetic rats Br J Pharmacol 140 2003 23 32
56. H. Kawaguchi, H. Sawa, and H. Yasuda Endothelin stimulates angiotensin I to angiotensin II conversion in cultured pulmonary artery endothelial cells J Mol Cell Cardiol 22 1990 839 842
57. W. Kim, and J.M. Egan The role of incretins in glucose homeostasis and diabetes treatment Pharmacol Rev 60 2008 470 512
58. T. Kobayashi, T. Nogami, K. Taguchi, T. Matsumoto, and K. Kamata Diabetic state, high plasma insulin and angiotensin II combine to augment endothelin-1-induced vasoconstriction via ETA receptors and ERK Br J Pharmacol 155 2008 974 983
59. D.E. Kohan, and D.M. Pollock Endothelin antagonists for diabetic and non-diabetic chronic kidney disease Br J Clin Pharmacol 76 2013 573 579
60. D.E. Kohan, Y. Pritchett, M. Molitch, S. Wen, T. Garimella, and P. Audhya Addition of atrasentan to renin-angiotensin system blockade reduces albuminuria in diabetic nephropathy J Am Soc Nephrol 22 2011 763 772
61. D.E. Kohan, N.F. Rossi, E.W. Inscho, and D.M. Pollock Regulation of blood pressure and salt homeostasis by endothelin Physiol Rev 91 2011 1 77
62. E.C. Leal, J. Martins, P. Voabil, J. Liberal, C. Chiavaroli, and J. Bauer Calcium dobesilate inhibits the alterations in tight junction proteins and leukocyte adhesion to retinal endothelial cells induced by diabetes Diabetes 59 2010 2637 2645
63. 2 + signaling, tyrosine phosphorylation, and coronary artery disease in diabetic dyslipidemic Swine are prevented by atorvastatin J Pharmacol Exp Ther 306 2003 132 140
64. A.M. Lefer, R. Scalia, and D.J. Lefer Vascular effects of HMG CoA-reductase inhibitors (statins) unrelated to cholesterol lowering: new concepts for cardiovascular disease Cardiovasc Res 49 2001 281 287
65. J.C. Liu, J.J. Chen, P. Chan, C.F. Cheng, and T.H. Cheng Inhibition of cyclic strain-induced endothelin-1 gene expression by resveratrol Hypertension 42 2003 1198 1205
66. X. Liu, Y. Deng, J. Shang, X.H. Yang, K. Liu, and H.G. Liu Effect of NADPH oxidase inhibitor apocynin on the expression of hypoxia-induced factor-1α and endothelin-1 in rat carotid body exposed to chronic intermittent hypoxia J Huazhong Univ Sci Technol Med Sci 33 2013 178 184
67. R. Lopez-Sepulveda, M. Gomez-Guzman, M.J. Zerzuelo, M. Romero, M. Sanchez, and A.M. Quintela Red wine polyphenols prevent endothelial dysfunction induced by endothelin-1 in rat aorta: role of NADPH oxidase Clin Sci 120 2011 321 333
68. A. Lteif, P. Vaishnava, A.D. Baron, and K.J. Mather Endothelin limits insulin action in obese/insulin-resistant humans Diabetes 56 2007 728 734
69. J.F. Mann, D. Green, K. Jamerson, L.M. Ruilope, S.J. Kuranoff, and T. Littke Avosentan for overt diabetic nephropathy J Am Soc Nephrol 21 2010 527 535
70. B.A. Maron, Y.Y. Zhang, K. White, S.Y. Chan, D.E. Handy, and C.E. Mahoney Aldosterone inactivates the endothelin-B receptor via a cysteinyl thiol redox switch to decrease pulmonary endothelial nitric oxide levels and modulate pulmonary arterial hypertension Circulation 126 2012 963 974
71. F. Martin-Nizard, C. Furman, P. Delerive, A. Kandoussi, J.C. Fruchart, and B. Staels Peroxisome proliferator-activated receptor activates inhibit oxidized low-density lipoprotein-induced endothelin-1 secretion in endothelial cells J Cardiovasc Pharmacol 40 2002 822 831
72. K.J. Mather The vascular endothelium in diabetes - a therapeutic target? Rev Endocr Metab Disord 14 2013 87 99
73. T. Matsumoto, E. Noguchi, T. Kobayashi, and K. Kamata Mechanisms underlying the chronic pioglitazone treatment-induced improvement in the impaired endothelium-dependent relaxation seen in aortas from diabetic rats Free Radic Biol Med 42 2007 993 1007
74. T. Matsumoto, T. Kobayashi, and K. Kamata Relationships among ET-1, PPARgamma, oxidative stress and endothelial dysfunction in diabetic animals J Smooth Muscle Res 44 2008 41 55
75. T. Matsumoto, K. Ishida, N. Nakayama, T. Kobayashi, and K. Kamata Involvement of NO and MEK/ERK pathway in enhancement of endothelin-1-induced mesenteric artery contraction in later-stage type 2 diabetic Goto-Kakizaki rat Am J Physiol Heart Circ Physiol 296 2009 H1388 H1397
76. T. Matsumoto, K. Ishida, K. Taguchi, T. Kobayashi, and K. Kamata Short-term angiotensin-1 receptor antagonism in type 2 diabetic Goto-Kakizaki rats normalizes endothelin-1-induced mesenteric artery contraction Peptides 31 2010 609 617
77. T. Matsumoto, S. Watanabe, R. Kawamura, and T. Kobayashi Epigallocatechin gallate attenuates ET-1-induced contraction in carotid and thoracic aorta from type 2 diabetic OLETF rat ET-13: International Conference on Endothelin (abstract) 2013
78. M.C. Michel, C. Foster, H.R. Brunner, and L. Liu A systematic comparison of the properties of clinically used angiotensin II type 1 receptor antagonists Pharmacol Rev 65 2013 809 848
79. J.S. Millar Novel benefits of peroxisome proliferator-activated receptors on cardiovascular risk Curr Opin Lipidol 24 2013 233 238
80. A. Mohanan, R. Gupta, A. Dubey, V. Jagtap, A. Mandhare, and R.C. Gupta TRC120038, a novel dual AT(1)/ET(A) receptor blocker for control of hypertension, diabetic dephropathy, and cardiomyopathy in ob-ZSF1 rats Int J Hypertens 2011 2011 751513
81. A.C. Montezano, F. Amiri, R.C. Tostes, R.M. Touyz, and E.L. Schiffrin Inhibitory effects of PPAR-gamma on endothelin-1-induced inflammatory pathways in vascular smooth muscle cells from normotensive and hypertensive rats J Am Soc Hypertens 1 2007 150 160
82. A.O. Mueck, H. Seeger, and T.H. Lippert Fluvastatin reduces endothelin secretion of cultured human umbilical vein endothelial cells Eur J Clin Pharmacol 55 1999 625 626
83. K.M. Munir, S. Chandrasekaran, F. Gao, and M.J. Quon Mechanisms for food polyphenols to ameliorate insulin resistance and endothelial dysfunction: implications for diabetes and its vascular complications Am J Physiol Endocrinol Metab 305 2013 E679 E686
84. R. Muniyappa, and J.R. Sowers Role of insulin resistance in endothelial dysfunction Rev Endocr Metab Disord 14 2013 5 12
85. T. Nakamura, C. Ushiyama, N. Shimada, K. Hayashi, I. Ebinara, and H. Koide Comparative effects of pioglitazone, glibenclamide, and voglibose on urinary endothelin-1 and albumin excretion in diabetes patients J Diabetes Complications 14 2000 250 254
86. T. Nakamura, C. Ushiyama, K. Hirokawa, S. Osada, N. Shimada, and H. Koide Effect of cerivastatin on urinary albumin excretion and plasma endothelin-1 concentrations in type 2 diabetes patients with microalbuminuria and dyslipidemia Am J Nephrol 21 2001 449 454
87. S. Nemoto, K. Taguchi, T. Matsumoto, K. Kamata, and T. Kobayashi Aminoguanidine normalizes ET-1-induced aortic contraction in type 2 diabetic Otsuka Long-Evans Tokushima Fatty (OLETF) rats by suppressing Jab1-mediated increase in ET(A)-receptor expression Peptides 33 2012 109 119
88. S. Nemoto, K. Taguchi, T. Matsumoto, K. Kamata, and T. Kobayashi Pravastatin normalizes ET-1-induced contraction in the aorta of type 2 diabetic OLETF rats by suppressing the KSR1/ERK complex Am J Physiol Heart Circ Physiol 303 2012 H893 H902
89. S.K. Nicholson, G.A. Tucker, and J.M. Brameld Physiological concentrations of dietary polyphenols regulate vascular endothelial cell expression of genes important in cardiovascular health Br J Nutr 103 2010 1398 1403
90. A. Novakovic, L. Gojkovic-Bukarica, M. Peric, D. Nezic, B. Djukanovic, and J. Markovic-Lipkovski The mechanism of endothelium-independent relaxation induced by the wine polyphenol resveratrol in human internal mammary artery J Pharmacol Sci 101 2006 85 90
91. M. Ohkita, M. Sugii, Y. Ka, A. Kitamura, T. Mori, and T. Hayashi Differential effects of different statins on endothelin-1 gene expression and endothelial NOS phosphorylation in porcine aortic endothelial cells Exp Biol Med 231 2006 772 776
92. F. Orio Jr., S. Palomba, T. Cascella, B. De Simone, F. Manguso, and S. Savastano Improvement in endothelial structure and function after metformin treatment in young normal-weight women with polycystic ovary syndrome: results of a 6-month study J Clin Endocrinol Metab 90 2005 6072 6076
93. K. Ozaki, T. Yamamoto, T. Ishibashi, T. Matsubara, M. Nishio, and Y. Aizawa Regulation of endothelial nitric oxide synthase and endothelin-1 expression by fluvastatin in human vascular endothelial cells Jpn J Pharmacol 85 2001 147 154
94. J.B. Park, and E.L. Schiffrin ET(A) receptor antagonist prevents blood pressure elevation and vascular remodeling in aldosterone-infused rats Hypertension 37 2001 1444 1449
95. M. Paul, A. Poyan Mehr, and R. Kreutz Physiology of local renin-angiotensin systems Physiol Rev 86 2006 747 803
96. P.E. Pergola, M. Krauth, J.W. Huff, D.A. Ferguson, S. Ruiz, and C.J. Meyer Effect of bardoxolone methyl on kidney function in patients with T2D and stage 3b-4 CKD Am J Nephrol 33 2011 469 476
97. P.E. Pergola, P. Raskin, R.D. Toto, C.J. Meyer, J.W. Huff, and E.B. Grossman Bardoxolone methyl and kidney function in CKD with type 2 diabetes N Engl J Med 365 2011 327 336
98. J. Pernow, A. Shemyakin, and F. Bohm New perspectives on endothelin-1 in atherosclerosis and diabetes mellitus Life Sci 91 2012 507 516
99. J.S. Pollock, and D.M. Pollock Endothelin, nitric oxide, and reactive oxygen species in diabetic kidney disease Contrib Nephrol 172 2011 149 159
100. K.E. Porter, and K. Riches The vascular smooth muscle cell: a therapeutic target in type 2 diabetes? Clin Sci 125 2013 167 182
101. M.A. Potenza, F.L. Marasciulo, M. Tarquinio, M.J. Quon, and M. Montagnari Treatment of spontaneously hypertensive rats with rosiglizatone and/or enalapril restores balance between vasodilator and vasoconstrictor actions of insulin with simultaneous improvement in hypertension and insulin resistance Diabetes 55 2006 3594 3603
102. Q. Pu, M.F. Neves, A. Virdis, R.M. Touyz, and E.L. Schiffrin Endothelin antagonism on aldosterone-induced oxidative stress and vascular remodeling Hypertension 42 2003 49 55
103. T. Pulido, I. Adzerikho, R.N. Channick, M. Delcroix, N. Gallie, and H.A. Ghofrani Macitentan and morbidity and mortality in pulmonary arterial hypertension N Engl J Med 369 2013 809 818
104. P. Quehenberger, A. Bierhaus, P. Fasching, C. Muellner, M. Klevesath, and M. Hong Endothelin 1 transcription is controlled by nuclear factor-kappaB in AGE-stimulated cultured endothelial cells Diabetes 49 2000 1561 1570
105. A.M. Quintela, R. Jimenez, M. Gomez-Guzman, M.J. Zarzuelo, P. Galindo, and M. Sanchez Activation of peroxisome proliferator-activated receptor-β/-δ (PPARβ/δ) prevents endothelial dysfunction in type 1 diabetic rats Free Radic Biol Med 53 2012 730 741
106. A. Rafnsson, F. Bohn, M. Settergren, A. Gonon, K. Brismar, and J. Pernow The endothelin receptor antagonist bosentan improves peripheral endothelial function in patients with type 2 diabetes mellitus and microalbuminuria: a randomized trial Diabetologia 55 2012 600 607
107. C.E. Reiter, J.A. Kim, and M.J. Quon Green tea polyphenol epigallocatechin gallate reduces endothelin-1 expression and secretion in vascular endothelial cells: roles for AMP-activated protein kinase, Akt, and FOXO1 Endocrinology 151 2010 103 114
108. G.P. Rossi, M. Cavallin, G.G. Nussdorfer, and A.C. Pessina The endothelin-aldosterone axis and cardiovascular diseases J Cardiovasc Pharmacol 38 2001 S49 S52
109. S. Russell Incretin-based therapies for type 2 diabetes mellitus: a review of direct comparisons of efficacy, safety and patient satisfaction Int J Clin Pharm 35 2013 159 172
110. C. Ruster, and G. Wolf Renin-angiotensin-aldosterone system and progression of renal disease J Am Soc Nephrol 17 2006 2985 2991
111. K. Sachidanandam, R. Hutchinson, M.M. Elgebaly, E.M. Mezzetti, A.M. Dorrance, and K. Motamed Glycemic control prevents microvascular remodeling and increased tone in type 2 diabetes: link to endothelin-1 Am J Physiol Regul Integr Comp Physiol 296 2009 R952 R959
112. E.L. Schiffrin Effects of aldosterone on the vasculature Hypertension 47 2006 312 318
113. C.A. Schmitt, E.H. Heiss, and V.M. Dirsch Effect of resveratrol on endothelial cell function: molecular mechanisms Biofactors 36 2010 342 349
114. J.G. Schneider, N. Tilly, T. Hierl, U. Sommer, A. Hamann, and K. Dugi Elevated plasma endothelin-1 levels in diabetes mellitus Am J Hypertens 15 2002 967 972
115. M. Settergren, J. Pernow, K. Brismar, G. Jorneskog, and M. Kalani Endothelin-A receptor blockade increases nutritive skin capillary circulation in patients with type 2 diabetes and microangiopathy J Vasc Res 45 2008 295 302
116. A. Shemyakin, F. Bohm, H. Wagner, S. Efendic, P. Bavenholm, and J. Pernow Enhanced endothelium-dependent vasodilatation by dual endothelin receptor blockade in individuals with insulin resistance J Cardiovasc Pharmacol 47 2006 385 390
117. A. Shemyakin, F. Salehzadeh, D. Esteves Duque-Guimarases, F. Bohm, E. Rullman, and R. Gustafsson Endothelin-1 reduces glucose uptake in human skeletal muscle in vivo and in vitro Diabetes 60 2011 2061 2067
118. J.R. Sowers Diabetes mellitus and vascular disease Hypertension 61 2013 943 947
119. A.D. Struthers Aldosterone-induced vasculopathy Mol Cell Endocrinol 217 2004 239 241
120. S. Sugo, N. Minamino, H. Shoji, Y. Isumi, K. Nakao, and K. Kangawa Regulation of endothelin-1 production in cultured rat vascular smooth muscle cells J Cardiovasc Pharmacol 37 2001 25 40
121. R.C. Tostes, and M.N. Muscara Endothelin receptor antagonists: another potential alternative for cardiovascular diseases Curr Drug Targets Cardiovasc Haematol Disord 5 2005 287 301
122. R.M. van Dam, N. Naidoo, and R. Landberg Dietary flavonoids and the development of type 2 diabetes and cardiovascular diseases: review of recent findings Curr Opin Lipidol 24 2013 25 33
123. B. Viollet, B. Guigas, N. Sanz Garcia, J. Leclerc, M. Foretz, and F. Andreelli Cellular and molecular mechanisms of metformin: an overview Clin Sci 122 2012 253 270
124. T. Wallerath, G. Deckert, T. Temes, H. Anderson, H. Li, and K. Witte Resveratrol, a polyphenolic phytoalexin present in red wine, enhances expression and activity of endothelial nitric oxide synthase Circulation 106 2002 1652 1658
125. C.J. Wang, J.T. Liu, and F. Guo (-)-Epigallocatechin gallate inhibits endothelin-1-induced C-reactive protein production in vascular smooth muscle cells Basic Clin Pharmacol Toxicol 107 2010 669 675
126. Z. Wang, A.S. Yadav, W. Leskova, and N.R. Harris Attenuation of streptozotocin-induced microvascular changes in the mouse retina with the endothelin receptor A antagonist atrasentan Exp Eye Res 91 2010 670 675
127. A.M. Watson, J. Li, C. Schumacher, M. de Gasparo, B. Feng, and M.C. Thomas The endothelin receptor antagonist avosentan ameliorates nephropathy and atherosclerosis in diabetic apolipoprotein E knockout mice Diabetologia 53 2010 192 203
128. R.R. Wenzel, J. Ruthemann, H. Bruck, R.F. Schafers, M.C. Michel, and T. Philipp Endothelin-A receptor antagonist inhibits angiotensin II and noradrenaline in man Br J Clin Pharmacol 52 2001 151 157
129. M.T. Win, Y. Yamamoto, S. Munesue, H. Saito, D. Han, and S. Motoyoshi Regulation of RAGE for attenuating progression of diabetic vascular complications Exp Diabetes Res 2012 2012 894605
130. C.B. Xu, E. Stenman, and L. Edvinsson Reduction of bFGF-induced smooth muscle cell proliferation and endothelin receptor mRNA expression by mevastatin and atorvastatin Biochem Pharmacol 64 2002 497 505
131. J. Yang, N. Wang, J. Li, J. Zhang, and P. Feng Effects of resveratrol on NO secretion stimulated by insulin and its dependence on SIRT1 in high glucose cultured endothelial cells Endocrine 37 2010 365 372
132. J. Yang, Y. Han, C. Chen, H. Sun, D. He, and J. Guo EGCG attenuates high glucose-induced endothelial cell inflammation by suppression of PKC and NF-κB signaling in human umbilical vein endothelial cells Life Sci 92 2013 589 597
133. M.J. Zarzuelo, M. Gomez-Guzman, R. Jimenez, A.M. Quintela, M. Romero, and M. Sanchez Effects of peroxisome proliferator-activated receptor-β activation in endothelin-dependent hypertension Cardiovasc Res 99 2013 622 631
134. Q. Zhou, K. Liu, H. Wu, L. Chen, V. Pouranan, and M. Yuan Spironolactone rescues Dot1a-Af9-mediated repression of endothelin-1 and improves kidney injury in streptozotocin-induced diabetic rats PLos One 7 2012 e47360